Our study demonstrated that COL3A1 exhibited the potency to become a prognostic biomarker for HNSCC, for it was more activated in cancer tissues than normal tissues, not only in the TCGA cohort but also in the practical patient cohort. Here, COL3A1 is linked to cancer.